Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) - October 14, 2025 Deadline to Join

Core Viewpoint - The Gross Law Firm is notifying shareholders of Unicycive Therapeutics, Inc. about a class action lawsuit due to alleged misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its new drug application [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 29, 2024, to June 27, 2025, Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [3]. - It is claimed that the regulatory prospects of the oxylanthanum carbonate new drug application were also overstated [3]. - As a result, the public statements made by the defendants were materially false and misleading throughout the relevant time [3]. Group 2: Class Action Details - Shareholders who purchased shares of UNCY during the specified class period are encouraged to register for the class action, with a deadline set for October 14, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].